Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer

PHASE1,PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped MTD was established and patients completed 16 months safety f-up and response assessments. It is considered of limited value to follow patients for 3 years.

Conditions

Head and Neck Cancer
Squamous Cell Cancer

Interventions

DRUG: zalutumumab
DRUG: cisplatin
PROCEDURE: Radiotherapy

Sponsor

Genmab